Validation of an Aptima-format Finnish new variant of Chlamydia trachomatis (FI-nvCT) surveillance assay, 2019

Euro Surveill. 2020 Feb;25(5):2000038. doi: 10.2807/1560-7917.ES.2020.25.5.2000038.

Abstract

The Finnish new variant of Chlamydia trachomatis (FI-nvCT) is escaping diagnostics in Finland, Norway and Sweden. We have developed and validated an Aptima-format nucleic acid amplification test (NAAT) designed specifically to detect the FI-nvCT. This NAAT has high sensitivity (100%) and specificity (100%) for the FI-nvCT strain, enabling further investigation of the geographic distribution, prevalence and transmission of this diagnostic-escape mutant in screening populations in Europe.

Keywords: Aptima Combo 2; Chlamydia trachomatis; Finish new variant; surveillance.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Chlamydia Infections / diagnosis*
  • Chlamydia Infections / epidemiology
  • Chlamydia Infections / microbiology
  • Chlamydia trachomatis / genetics*
  • Chlamydia trachomatis / isolation & purification
  • Finland / epidemiology
  • Genetic Variation / genetics*
  • Humans
  • Nucleic Acid Amplification Techniques / methods*
  • Polymerase Chain Reaction
  • RNA, Bacterial / genetics
  • Reproducibility of Results
  • Sensitivity and Specificity
  • Sequence Analysis, RNA / methods*

Substances

  • RNA, Bacterial